Alentis Therapeutics has in-licensed several monoclonal antibodies which target a cell surface protein recently discovered as a driver for liver disease and cancer.

The compounds act by a novel mechanism of action and provide an innovative approach which holds promise for treating liver fibrosis and cancer.

The approach may also provide the opportunity for treatment of other types of fibrosis or cancer.

Alentis’ lead monoclonal antibody has shown robust preclinical proof-of-concept in a large series of model systems including patient-derived tissues and human liver and cancer models.